Bonus Biogroup Ltd. · TASE:BONS
Bonus Biogroup — Investor Presentation (July 2016)
19 slides from Bonus Biogroup's investor presentation, July 2016
Slide 1: Bonus BioGroup: Innovative tissue regeneration technologies
Innovative tissue regeneration technologies Bonus BioGroup
Slide 2: Disclaimer and forward-looking statement
Disclaimer and forward-looking statement This presentation has been prepared by Bonus BioGroup Ltd. using its best efforts to realistically and factually present the information contained. However, subjective opinion, dependence upon factors outside Bonus's control and outside information sources un
Slide 3: Overview
Overview Biotechnology company applying an innovative technology to generate viable tissue-engineered bone grafts. The company is targeting a multi-billion dollar worldwide market for the treatment of skeletal disorders. The company was founded by experts in the field of tissue engineering and cell
Slide 4: Our Vision
Our Vision Bonus BioGroup aims to become a global leader in the field of tissue engineering and live bone transplantation.
Slide 5: Leadership
Leadership Shai Meretzki, Ph.D., Founder, CEO and President Dr. Meretzki has proven operational, management and leadership abilities in Life Science companies. Former founder, CEO and CTO of Pluristem Life Systems, Inc. (NASDAQ: PSTI; TASE: PLTR). Also serves as chairman of the board at Biological I
Slide 6: Leadership
Leadership Yoni Livne, CPA – Chief Financial Officer Mr. Livne has been serving as Chief Financial Officer since 2014. Before joining Bonus BioGroup, Mr. Livne was Chief Financial Officer at Bee Contact Communication Ltd., a publicly traded company (TASE), and Chief Controller at Dexcel Pharma, a pr
Slide 7: Bone Regeneration Market
Bone Regeneration Market Natural bone has the ability to repair itself in response to injury. However, in complex clinical Bone market growth is conditions normal bone regeneration is impaired. These cases include large bone defects created by aging, trauma, infection, tumor resection and skeletal a
Slide 8: Bone grafts: Current Solutions
Bone grafts: Current Solutions Autologous bone graft – The gold standard Bone is relocated from one location to another in the patient's body. Limitations: Invasive surgical procedure, donor site morbidity, insufficient graft volume and quality. 9% 16% Allografts/DBM 48% Bone grafts obtained from hu
Slide 9: Our solution - BonoFill
Our solution - BonoFillTM BonoFill is a novel, autologous, tissue-engineered bone graft aims to replace current inferior solutions. BonoFill Advantages: • High quality bone graft which is • Available in large quantities. Viability & Availability & biologically and histologically • Repairing a broad
Slide 10: Technology
Technology Bonus BioGroup has developed a unique technology to grow bone graft, from cells isolated from the patient’s fat tissue. Bone Liposuction t ra n s p l a ntat i o n B o n e fo r ma t i o n Cells isolation C e l l s g ro w t h o n s ca f fo l d i n a b i o re a c to r
Slide 11: BonoFill Properties
BonoFillTM Properties Autologous cell source: Grown from the patient's adipose-derived cells, harvested in a simple procedure termed liposuction, eliminating the risk of tissue rejection and surgery failure. Multi-cell bone graft: Contains both mature and premature bone forming cells, which maintain
Slide 12: Solid Bone Application
Solid Bone Application Anatomically pre-designed bone graft: The bone forming cells are isolated from the patient’s adipose tissue sample and grown in a bioreactor, on a scaffold. The scaffold is predesign to precisely match the patient's 3D bone gap by Computed Tomography (CT) image. The bone-induc
Slide 13: Injectable Bone Application
Injectable Bone Application Injectable BonoFill™ The bone forming cells are isolated from the patient’s adipose tissue sample and grown in a bioreactor, on mineral particles. BonoFillTM is an injectable bone graft, provided in a prefilled syringe, Appropriate for the treatment of bounded bone defect
Slide 14: Preclinical Results
Preclinical Results BonoFill transplantation in cranial critical sized bone defect preclinical model Control Bone Volume Control BonoFillTM BonoFillTM 8 6 mm3 0 weeks 4 2 0 4W 6w 4 weeks Bone Surface 60 40 mm2 6 weeks 20 0 4W 6w
Slide 15: Preclinical Results
Preclinical Results BonoFill transplantation in the preclinical model: Intra-femoral bone injection Intra-femoral injection preclinical model Control BonoFillTM (three wall gap) Trabecular bone Saline injection and bone marrow flushing Trabecular mask BonoFill or Control Injection Micro-CT scan of t
Slide 16: Manufacturing Facility
Manufacturing Facility The facility was designed for the generation of live human bone grafts and constructed in compliance with FDA and EMEA requirements for manufacturing of biological products. The facility is Good Manufacturing Practice (GMP) and ISO-9001-certified.
Slide 17: Clinical Trial
Clinical Trial Maxillofacial bone regeneration (2014) Clinical evaluation of BonoFillTM is currently being done in phase I/II, open label, first in human, clinical study. For maxillofacial bone regeneration, in two clinical indications: 1. Bone augmentation 2. Filling bone void following cyst remova
Slide 18: Product pipeline
Product pipeline Product Preclinical phase Clinical phase Bone graft for maxillofacial applications Strategic Partners Bone graft for orthopedic applications Combined bone & cartilage (osteochondral) graft for joint repair BIRD Foundation - Israel-U.S. Binational Industrial R&D Novel nanomaterials t
Slide 19: Why Us?
Why Us? Short and inexpensive regulation process Flexible technology platform for a variety of clinical indications High entry barrier for competition Billion dollars market potential Experienced management and R&D team, with a proven track record Contact Us: info@bonus-bio.com